CD19 and lymphoma: Indeed, the identification of CD19 as a target antigen for B‐cell leukaemias and lymphomas has allowed the development of FDA‐approved CD19‐targeting CAR‐T cell therapies that have been used to successfully treat thousands of patients, many of whom remain disease‐free several years after treatment, all via targeting a single antigen.11